Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia

Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia

Paclitaxel is chemotherapeutic agent used in many of the most common anti-cancer regimens. Its use is frequently associated with moderate to severe muscle and joint pain that may persist for several days after the treatment. This side effect, known as "Arthralgia-Myalgia Syndrome, has a significant impact on the quality of life and functional abilities of those receiving the treatment, and is not alleviated by many of the interventions attempted for that purpose.

Sporadic reports suggest that a drug called gabapentin may be effective in the management of this adverse effect. Observations from our practice indicate that pregabalin, which possesses similar biological activity to that of gabapentin, may also be useful in preventing and treating paclitaxel associated myalgia - arthralgia.

The current study represents an initial evaluation of the hypothesis that pregabalin may be beneficial in the management of the symptoms due to the "Arthralgia-Myalgia Syndrome". The investigation will be carried out in the format of a small scale, randomized, placebo controlled trial with patients receiving paclitaxel in the course of standard treatment for breast cancer.

Taxane Related Arthralgia-Myalgia Syndrome:

Paclitaxel and docetaxel are the major representatives of the drug class of taxanes, agents commonly used in the treatment of a variety of solid tumors. They interfere with the mitotic process of dividing cells by stabilizing the microtubules and are the mainstay of treatment in lung, breast, and ovarian cancer, among others. The adverse side effects associated with taxane treatment frequently impair the quality of life of cancer patients and occasionally impose discontinuation of the oncological treatment of choice (Forsyth, Balmaceda et al. 1997; Saibil, Fitzgerald et al. 2010).

The phenomenon of diffuse pain involving joints and muscles in the wake of treatment with taxanes commonly referred to as Taxane related Arthralgia-Myalgia Syndrome (from here on noted as TAMS) is well known and documented (Rowinsky, Chaudhry et al. 1993). It is common, as apparent from a recent retrospective study of patients treated with regimens used for breast cancer which revealed an 80% incidence of taxane related pain (Saibil, Fitzgerald et al. 2010).

The pain may be localized, regional or diffuse, most commonly in the back, hips, shoulders, thighs, legs and feet (Loprinzi, Maddocks-Christianson et al. 2007). It is usually depicted as arthralgia-myalgia due to the difficulty to associate it clearly with either the joints or the muscles (Loprinzi, Maddocks-Christianson et al. 2007). The nature of the sensation is described as aching, deep pain, often with associated radiating, shooting, stabbing, pulsating elements (Loprinzi, Maddocks-Christianson et al. 2007). The sensation is of unique quality previously unencountered by those experiencing it, the description of which is not compatible with established reports of neuropathic pain.

The syndrome may be of incapacitating intensity, capable of imposing days of bed restriction on those suffering from it. This burden is often extended to significant others who have to remain and care for the daily needs of those handicapped by the pain. Attempts of treatment with steroids, non-steroid anti-inflammatory drugs and opioid analgesics frequently fail to produce satisfactory results (Garrison, McCune et al. 2003).

Pregabalin - Basic Pharmacology and Potential for Treatment of TAMS:

Pregabalin is a small molecule with an established efficacy in the treatment of neuropathic pain (Gajraj 2007). It is known to interact with the α2-δ subunit of voltage gated calcium channels present in multiple tissues, most prominently in brain and muscle (Taylor, Angelotti et al. 2007).

Pregabalin is rapidly absorbed via a specialized transport system, reaching a peak concentration in the serum circa one hour after oral ingestion (Gajraj 2005). Bioavailability exceeds 90% and the pharmacokinetic profile is linear throughout the clinically relevant concentrations (Gajraj 2005). It does not bind significantly to proteins in the blood stream, does not undergo any modification during its passage through the organism, and is eliminated unchanged in the urine (Gajraj 2005). No significant pharmacokinetic interactions have been reported to date (Gajraj 2007).

Currently pregabalin is being used in the treatment of neuropathic pain and as an anti-epileptic agent (Gajraj 2007). Accumulated evidence is supportive of a high degree of safety in its use, with the most common side effects constituting of mild to moderate degree dizziness, somnolence, feeling drunk, fatigue and increased weight (Harmark, van Puijenbroek et al. 2011).

Sporadic reports suggest that gabapentin may be effective in alleviating Taxol related arthralgia-myalgia symptoms (Nguyen and Lawrence 2004). On grounds of similar pharmacodynamics (Bryans and Wustrow 1999) it may be hypothesized that pregabalin also has potential to alleviate the paclitaxel related arthralgia-myalgia. Furthermore, observations from our clinical oncology service are supportive of this hypothesis.

Evaluation of the Taxane Related Arthralgia-Myalgia Syndrome:

Pain constitutes a major component of the Taxane related Arthralgia-Myalgia Syndrome (from here on referred to as TAMS) (Garrison, McCune et al. 2003). We propose that pregabalin may have a significantly beneficial effect on the pain secondary to this syndrome. Consequently, evaluation of the pain before and after treatment with the study drug by means of a well established pain scoring method is required.

Modern pain research acknowledges the subjective and complex nature of pain that complicates its assessment. Furthermore, ethical imperatives place constraints on the comparative control to serve the in evaluation of a novel analgesic intervention (Silverman, O'Connor et al. 1993). One of the solutions to this issue, using normalized ordinal evaluations of pain and analgesic drug consumption around a central value in a manner that also accounts for changes in analgesic drug requirements (Silverman, O'Connor et al. 1993) will serve for direct assessment of the study hypothesis.

The Integrated Assessment of Pain Score and Rescue Analgesic Treatment evaluation according to Silverman et al will be augmented by raw pain assessment by means of a well established pain scoring method (Farrar, Portenoy et al. 2000).

Bed restriction is a direct result of the TAMS that is often described by those suffering from it. It is hereby proposed to monitor bed restriction by recording the number of hours spent in horizontal position between the time of getting up from the night's sleep and the hour of going to bed at the end of the day. The proposed measure will compare the number of hours spent in the horizontal position on the day preceding the taxane treatment, and the number of hours spent in that position on the day with the highest score of pain during the week following treatment. The sample size is not calculated to serve the validation of this novel measure, but an effort to assess its association with established quality-of-life scores will be made.

The current proposal is focused on evaluating an intervention with potential to have a positive impact on the quality of life of individuals receiving chemotherapy with taxanes. The FACT-Taxane scale is a psychometric tool specifically developed to assess the impact of taxane based treatment (Cella, Peterman et al. 2003). However, quality of life is a composite measure, and requires a larger sample size to determine efficacy, and therefore it will only serve as a secondary endpoint.

Screening Criteria:

• Signature of consent form.
• Legal competence for expression of consent.
• Patients with confirmed diagnosis of cancer of breast, free of confounding pain before the administration of chemotherapy.
• Recommendation for treatment with paclitaxel containing protocols, prior to initiation of chemotherapy.
• Age over 18.

Inclusion criteria for treatment phase:

• Fulfillment of screening criteria.
• Experience of myalgia-arthralgia related pain of moderate or worse degree of severity after a course of paclitaxel containing chemotherapy.

Exclusion Criteria:

• Ongoing treatment with pregabalin or gabapentin.
• Known restricting adverse events related to treatment with pregabalin or gabapentin.
• Renal failure with GFR less than 30ml/min.
• Participation in clinical trial 3 weeks or less prior to screening.
• Confounding myalgia and / or arthralgia unrelated to chemotherapy.
• Medical condition compromising the likelihood of completing the trial.